Skip to main content

CytRx's RXi Business Exclusively Licenses Invitrogen's RNAi IP for Rx Apps

NEW YORK (GenomeWeb News) — CytRx subsidiary RXi Pharmaceuticals will exclusively license Invitrogen’s second-generation RNAi technology for “designated target genes in all human therapeutic categories,” the companies said today.
 
The intellectual property covers Invitrogen’s Stealth technology and other tools related to chemically modified double-stranded RNA.
 
RXi CEO Tod Woolf said in a statement that the deal is “part of our strategy to enhance our proprietary rxRNA compounds for therapeutic applications.”
 
CytRx currently owns three clinical-stage compounds that use its small-molecule “molecular chaperone” co-induction technology, including candidates to treat amyotrophic lateral sclerosis, diabetic foot ulcers, and stroke recovery.
 
Invitrogen’s Stealth RNAi synthetic duplexes are used for RNAi research across both in vitro and in vivo applications, Amy Butler, Invitrogen vice president of gene-expression profiling, said in a statement.
 
She said the company sees the use of the technology in therapeutics as “a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.